Latest news
Ocular Therapeutix: Over 90% Of Surveyed Retina Specialists Expected To Adopt AXPAXLI In First Year - pulse2.compulse2.com · Tue, 04 Aug 2026 18:09:33 GMTOcular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says - marketscreener.commarketscreener.com · Tue, 04 Aug 2026 16:00:37 GMTAXPAXLI Shows 72% Reduction in Injection Burden vs Aflibercept in Wet AMD - The Clinical Trial VanguardThe Clinical Trial Vanguard · Tue, 04 Aug 2026 06:43:26 GMTOcular Therapeutix (OCUL) Stock Faces Axpaxli Hopes Against Deepening Losses - simplywall.stsimplywall.st · Tue, 04 Aug 2026 02:24:11 GMTOCUL Stock In Spotlight After Q2 Loss Comes In Narrower Than Estimated – A Look At Key Highlights - TradingViewTradingView · Mon, 03 Aug 2026 12:48:47 GMTOcular Therapeutix reports Q2 2026: $13.5M revenue, $78.8M net loss, $598.6M cash - TradingViewTradingView · Mon, 03 Aug 2026 11:23:01 GMTOCUL: Strong Phase 3 data for AXPAXLI drives NDA plans, but losses widen as R&D and launch costs rise - TradingViewTradingView · Mon, 03 Aug 2026 11:17:23 GMTOCUL: AXPAXLI NDA submission set for Q4 2026, with strong trial results and cash runway into 2028 - TradingViewTradingView · Mon, 03 Aug 2026 11:12:32 GMT